ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS SECRETS

In Phase A, members will obtain distinct doses and schedules of oral ABBV-744 pill to detect Harmless dosing routine. Further participants will be enrolled at the recognized monotherapy dosign regimen. In Section B, participants will acquire oral ruxolitinib and ABBV-744 might be presented as "include-on" therapy. In Phase C, individuals will obtai